528 related articles for article (PubMed ID: 25403681)
1. Treatment of lupus nephritis with abatacept: the Abatacept and Cyclophosphamide Combination Efficacy and Safety Study.
ACCESS Trial Group
Arthritis Rheumatol; 2014 Nov; 66(11):3096-104. PubMed ID: 25403681
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study.
Furie R; Nicholls K; Cheng TT; Houssiau F; Burgos-Vargas R; Chen SL; Hillson JL; Meadows-Shropshire S; Kinaszczuk M; Merrill JT
Arthritis Rheumatol; 2014 Feb; 66(2):379-89. PubMed ID: 24504810
[TBL] [Abstract][Full Text] [Related]
3. Abatacept for lupus nephritis: alternative definitions of complete response support conflicting conclusions.
Wofsy D; Hillson JL; Diamond B
Arthritis Rheum; 2012 Nov; 64(11):3660-5. PubMed ID: 22806274
[TBL] [Abstract][Full Text] [Related]
4. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide.
Houssiau FA; Vasconcelos C; D'Cruz D; Sebastiani GD; Garrido Ed Ede R; Danieli MG; Abramovicz D; Blockmans D; Mathieu A; Direskeneli H; Galeazzi M; Gül A; Levy Y; Petera P; Popovic R; Petrovic R; Sinico RA; Cattaneo R; Font J; Depresseux G; Cosyns JP; Cervera R
Arthritis Rheum; 2002 Aug; 46(8):2121-31. PubMed ID: 12209517
[TBL] [Abstract][Full Text] [Related]
5. Leflunomide versus cyclophosphamide in the induction treatment of proliferative lupus nephritis in Chinese patients: a randomized trial.
Zhang M; Qi C; Zha Y; Chen J; Luo P; Wang L; Sun Z; Wan J; Xing C; Wang S; Jiang G; Sun M; Chen Q; Chen J; Li D; Guan T; Ni Z
Clin Rheumatol; 2019 Mar; 38(3):859-867. PubMed ID: 30426311
[TBL] [Abstract][Full Text] [Related]
6. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial.
Houssiau FA; Vasconcelos C; D'Cruz D; Sebastiani GD; de Ramon Garrido E; Danieli MG; Abramovicz D; Blockmans D; Mathieu A; Direskeneli H; Galeazzi M; Gül A; Levy Y; Petera P; Popovic R; Petrovic R; Sinico RA; Cattaneo R; Font J; Depresseux G; Cosyns JP; Cervera R
Arthritis Rheum; 2004 Dec; 50(12):3934-40. PubMed ID: 15593207
[TBL] [Abstract][Full Text] [Related]
7. Comparison of alternative primary outcome measures for use in lupus nephritis clinical trials.
Wofsy D; Hillson JL; Diamond B
Arthritis Rheum; 2013 Jun; 65(6):1586-91. PubMed ID: 23529285
[TBL] [Abstract][Full Text] [Related]
8. Comparing the efficacy of low-dose vs high-dose cyclophosphamide regimen as induction therapy in the treatment of proliferative lupus nephritis: a single center study.
Mehra S; Usdadiya JB; Jain VK; Misra DP; Negi VS
Rheumatol Int; 2018 Apr; 38(4):557-568. PubMed ID: 29450636
[TBL] [Abstract][Full Text] [Related]
9. Health-related quality of life and treatment burden in patients with proliferative lupus nephritis treated with cyclophosphamide or azathioprine/ methylprednisolone in a randomized controlled trial.
Grootscholten C; Snoek FJ; Bijl M; van Houwelingen HC; Derksen RH; Berden JH;
J Rheumatol; 2007 Aug; 34(8):1699-707. PubMed ID: 17659757
[TBL] [Abstract][Full Text] [Related]
10. Combined immunosuppressive treatment (CIST) in lupus nephritis: a multicenter, randomized controlled study.
An Y; Zhou Y; Bi L; Liu B; Wang H; Lin J; Xu D; Wang M; Zhang J; Wang Y; An Y; Zhu P; Xie R; Zhang Z; Mei Y; Liu X; Deng X; Yao Z; Zhang Z; Wang Y; Xiao W; Shen H; Yang X; Xu H; Yu F; Wang G; Lu X; Li Y; Li Y; Zuo X; Li Y; Liu Y; Zhao Y; Guo J; Sun L; Zhao M; Li Z
Clin Rheumatol; 2019 Apr; 38(4):1047-1054. PubMed ID: 30488367
[TBL] [Abstract][Full Text] [Related]
11. Treatment with cyclophosphamide delays the progression of chronic lesions more effectively than does treatment with azathioprine plus methylprednisolone in patients with proliferative lupus nephritis.
Grootscholten C; Bajema IM; Florquin S; Steenbergen EJ; Peutz-Kootstra CJ; Goldschmeding R; Bijl M; Hagen EC; Van Houwelingen HC; Derksen RH; Berden JH;
Arthritis Rheum; 2007 Mar; 56(3):924-37. PubMed ID: 17328070
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study.
Mysler EF; Spindler AJ; Guzman R; Bijl M; Jayne D; Furie RA; Houssiau FA; Drappa J; Close D; Maciuca R; Rao K; Shahdad S; Brunetta P
Arthritis Rheum; 2013 Sep; 65(9):2368-79. PubMed ID: 23740801
[TBL] [Abstract][Full Text] [Related]
13. Comparative efficacy and safety of tacrolimus, mycophenolate mofetil, azathioprine, and cyclophosphamide as maintenance therapy for lupus nephritis : A Bayesian network meta-analysis of randomized controlled trials.
Lee YH; Song GG
Z Rheumatol; 2017 Dec; 76(10):904-912. PubMed ID: 27638015
[TBL] [Abstract][Full Text] [Related]
14. Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis.
Furie R; Rovin BH; Houssiau F; Malvar A; Teng YKO; Contreras G; Amoura Z; Yu X; Mok CC; Santiago MB; Saxena A; Green Y; Ji B; Kleoudis C; Burriss SW; Barnett C; Roth DA
N Engl J Med; 2020 Sep; 383(12):1117-1128. PubMed ID: 32937045
[TBL] [Abstract][Full Text] [Related]
15. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis.
Ginzler EM; Dooley MA; Aranow C; Kim MY; Buyon J; Merrill JT; Petri M; Gilkeson GS; Wallace DJ; Weisman MH; Appel GB
N Engl J Med; 2005 Nov; 353(21):2219-28. PubMed ID: 16306519
[TBL] [Abstract][Full Text] [Related]
16. Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide.
Contreras G; Tozman E; Nahar N; Metz D
Lupus; 2005; 14 Suppl 1():s33-8. PubMed ID: 15803929
[TBL] [Abstract][Full Text] [Related]
17. Crossing the Atlantic: the Euro-Lupus Nephritis regimen in North America.
Wofsy D; Diamond B; Houssiau FA
Arthritis Rheumatol; 2015 May; 67(5):1144-6. PubMed ID: 25779381
[No Abstract] [Full Text] [Related]
18. Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial.
Mease P; Genovese MC; Gladstein G; Kivitz AJ; Ritchlin C; Tak PP; Wollenhaupt J; Bahary O; Becker JC; Kelly S; Sigal L; Teng J; Gladman D
Arthritis Rheum; 2011 Apr; 63(4):939-48. PubMed ID: 21128258
[TBL] [Abstract][Full Text] [Related]
19. Rituximab vs mycophenolate and vs cyclophosphamide pulses for induction therapy of active lupus nephritis: a clinical observational study.
Moroni G; Raffiotta F; Trezzi B; Giglio E; Mezzina N; Del Papa N; Meroni P; Messa P; Sinico AR
Rheumatology (Oxford); 2014 Sep; 53(9):1570-7. PubMed ID: 24505125
[TBL] [Abstract][Full Text] [Related]
20. High-dose azathioprine pulse therapy as a new treatment option in patients with active Wegener's granulomatosis and lupus nephritis refractory or intolerant to cyclophosphamide.
Benenson E; Fries JW; Heilig B; Pollok M; Rubbert A
Clin Rheumatol; 2005 Jun; 24(3):251-7. PubMed ID: 15940558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
